Loading
ATM is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. This dossier gathers the 0 products (0 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Serine/threonine protein kinase which activates checkpoint signalling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionising ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognises the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. Location: Nucleus; Cytoplasmic vesicle; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Peroxisome matrix (UniProt). Locus 11q22.3 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Gallbladder cancer | 7-16% | Mutation | Mutation in 16 of 244 samples, 6.6%, in cBioPortal gbc_mskcc_2022 and 16 of 103, 15.5%, in gbc_msk_2018; among the actionable variants in the Chilean cohort (Erices 2025). | cBioPortal (TCGA) |
| Prostate cancer | 3-11% | Inactivating mutation, germline or somatic | cBioPortal mutation: 20 of 494, 4.0%, in prad_tcga_pan_can_atlas_2018; 8 of 477, 1.7%, in prad_cpcg_2017; 38 of 1,013, 3.8%, in prad_p1000; 24 of 424, 5.7%, in prad_mcspc_mskcc_2020; 96 of 2,260, 4.2%, in prostate_msk_2024; 27 of 444, 6.1%, in prad_su2c_2019; 16 of 141, 11.3%, in prad_fhcrc. Germline: 11 of 692 men with metastatic disease, 1.6% (Pritchard 2016). | cBioPortal (TCGA) |
| Pancreatic ductal adenocarcinoma | 1.2-2.3% | Germline pathogenic variant (somatic in a further 3 to 4%) | 2.3% of 3,030 against 0.37% of controls, odds ratio 5.71 (Hu 2018); 10 of 854, 1.2% (Shindo 2017); ATM among the new significantly mutated genes in 99 exomes (Biankin 2012). Tumour sequencing: 69 of 2,336, 3.0%, in pdac_msk_2024; 14 of 383, 3.7%, in paad_qcmg_uq_2016; 8 of 179, 4.5%, in paad_tcga_pan_can_atlas_2018 (cBioPortal). Germline ATM carriers with one affected first-degree relative became eligible for CAPS surveillance in 2020 (Goggins 2020). | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
TRITON3 NCT02975934 | 3 | Mixed | Metastatic castration-resistant prostate cancer with a BRCA1, BRCA2 or ATM alteration and progression after a second-generation androgen receptor pathway inhibitor: rucaparib 600 mg twice daily against physician's choice of docetaxel or a second androgen receptor pathway inhibitor, randomised 2:1, with imaging-based progression-free survival by independent review as the primary outcome | Median imaging-based progression-free survival 11.2 against 6.4 months in the BRCA subgroup (hazard ratio 0.50, 95 percent confidence interval 0.36 to 0.69) and 10.2 against 6.4 months overall (0.61, 0.47 to 0.80); no effect in the ATM subgroup (0.95, 0.59 to 1.52). |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"ATM" OR ABSTRACT:"ATM" OR TITLE:"ATM serine/threonine kinase" OR ABSTRACT:"ATM serine/threonine kinase" OR TITLE:"Serine-protein kinase ATM" OR ABSTRACT:"Serine-protein kinase ATM" OR TITLE:"TEL1" OR ABSTRACT:"TEL1" OR TITLE:"TELO1" OR ABSTRACT:"TELO1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATM, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/atm.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/atm.json. Licence CC BY-NC 4.0.